A Korean research team jointly led by Professor Chan Beum Park of the Materials Science and Engineering Department at KAIST and Dr. Kwon Yu from the Bionano Center at the Korea Research Institute of Bioscience and Biotechnology (KRIBB) conducted research to suppress an abnormal assembly of beta-amyloids, a protein commonly found in the brain, by using photo-excited porphyrins.
Beta-amyloid plaques are known to cause Alzheimer’s disease. This research finding suggests new ways to treat neurodegenerative illnesses including Alzheimer’s disease. It was published online as the lead article in the September 21th issue of Angewandte Chemie. The title of the article is “Photo-excited Porphyrins as a Strong Suppressor of ß-Amyloid Aggregation and Synaptic Toxicity.”
Light-induced treatments using organic photosensitizers have advantages to managing the treatment in time and area. In the case of cancer treatments, doctors use photodynamic therapies where a patient is injected with an organic photosensitizer, and a light is shed on the patient’s lesion. However, such therapies had never been employed to treat neurodegenerative diseases.
Alzheimer’s starts when a protein called beta-amyloid is created and deposited in a patient’s brain. The abnormally folded protein created this way harms the brain cells by inducing the degradation of brain functions, for example, dementia. If beta-amyloid creation can be suppressed at an early stage, the formation of amyloid deposits will stop. This could prevent Alzheimer’s disease or halt its progress.
The research team effectively prevented the buildup of beta-amyloids by using blue LED lights and a porphyrin inducer, which is a biocompatible organic compound. By absorbing light energy, a photosensitizer such as porphyrin reaches the excitation state. Active oxygen is created as the porphyrin returns to its ground state. The active oxygen oxidizes a beta-amyloid monomer, and by combining with it, disturbs its assembly.
The technique was tested on drosophilae or fruit flies, which were produced to model Alzheimer on invertebrates. The research showed that symptoms of Alzheimer’s disease in the fruit flies such as damage on synapse and muscle, neuronal apoptosis, degradation in motility, and decreased longevity were alleviated. Treatments with light provide additional benefits: less medication is needed than other drug treatments, and there are fewer side effects. When developed, photodynamic therapy will be used widely for this reason.
Professor Park said,
“This work has significance as it was the first case to use light and photosensitizers to stop deposits of beta-amyloids. We plan to carry the research further by testing compatibility with other organic and inorganic photosensitizers and by changing the subject of photodynamic therapy to vertebrate such as mice.”
Read more: Using Light to Treat Alzheimer’s Disease
The Latest on: Photodynamic therapy
via Google News
The Latest on: Photodynamic therapy
- Biofrontera reports results for the 2020 financial yearon April 12, 2021 at 10:57 am
The company’s lead product is the combination of Ameluz®, a topical prescription drug, and medical device BF-RhodoLED® for the photodynamic therapy of certain superficial skin cancers and their ...
- Rocky Hill biotech firm raises $4.3 million, set to begin clinical testingon April 8, 2021 at 5:00 pm
Rocky Hill-based medical technology firm Lumeda, which is developing a lung cancer-killing light therapy system, raised $4.3 million through its Series A funding round and now expects to start human ...
- Tailoring photosensitive ROS for advanced photodynamic therapyon April 8, 2021 at 10:19 am
Photodynamic therapy (PDT) has been considered a noninvasive and cost-effective modality for tumor treatment. However, the complexity of tumor microenvironments poses challenges to the implementation ...
- Soligenix Receives Conditional FDA Acceptance of Proposed Brand Name HyBryte™ for SGX301 in CTCLon April 7, 2021 at 4:12 am
About HyBryte™ HyBryte™ (SGX301) is a novel first-in-class photodynamic therapy utilizing safe visible light for activation. The active ingredient in HyBryte™ is synthetic hypericin ...
- Soligenix Receives Conditional FDA Acceptance of Proposed Brand Name HyBryte™ for SGX301 in CTCLon April 7, 2021 at 4:00 am
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet ...
- Photodynamic therapy as a treatment option for peripapillary pachychoroid syndrome: a pilot studyon April 5, 2021 at 5:00 pm
Fig. 1: Multimodal imaging of a 71-year-old male patient with peripapillary pachychoroid syndrome undergoing half-fluence full-dose photodynamic therapy. Fig. 2: Change in central subfield thickness ...
- Biofrontera submits application for FDA approval of new BF-RhodoLED® XL lampon March 31, 2021 at 12:54 am
significantly larger red-light source for photodynamic therapy (PDT) to be used in combination with Ameluz®, the BF-RhodoLED® XL, to the U.S. Food and Drug Administration (FDA). The new BF ...
- Biofrontera submits application for FDA approval of new BF-RhodoLED® XL lampon March 30, 2021 at 8:41 pm
significantly larger red-light source for photodynamic therapy (PDT) to be used in combination with Ameluz ®, the BF-RhodoLED ® XL, to the U.S. Food and Drug Administration (FDA). The new BF-RhodoLED ...
- Soligenix Announces Recent Accomplishments And Year-End 2020 Financial Resultson March 30, 2021 at 4:30 am
Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical ...
via Bing News